Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2154441 | 0.76 | CES1 (0.48) | CES2CES1ALDH1A1AKR1B1KDM4E | |
| SCHEMBL6295378 | 0.76 | CES2 (0.48) | CES2CES1ALDH1A1AKR1B1KDM4E | |
| SCHEMBL2700591 | 0.74 | CES2 (0.46) | CES2CES1ALDH1A1AKR1B1KDM4E | |
| SCHEMBL66063 | 0.73 | CES1 (0.50) | CES2CES1ALDH1A1AKR1B1MEN1 | |
| SCHEMBL1870609 | 0.73 | ALDH1A1 (0.62) | CES2CES1ALDH1A1AKR1B1KDM4E | |
| SCHEMBL13176469 | 0.73 | ALDH1A1 (0.44) | CES2CES1ALDH1A1AKR1B1KDM4E | |
| SCHEMBL7324968 | 0.73 | ALDH1A1 (0.45) | CES2CES1ALDH1A1AKR1B1KDM4E | |
| SCHEMBL6299815 | 0.73 | ALDH1A1 (0.44) | CES2CES1ALDH1A1AKR1B1KDM4E | |
| Benzene SCHEMBL28096336 | 0.73 | ALDH1A1 (0.62) | CES2CES1ALDH1A1AKR1B1KDM4E | |
| SCHEMBL16618549 | 0.73 | ALDH1A1 (0.49) | CES2CES1ALDH1A1AKR1B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903990-B1 | THERAPEUTICALLY ACTIVE OXAZOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2017-06-14 | — | — | EP | disclosed |
| EP-2744812-B1 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-07-20 | — | — | EP | disclosed |
| US-9382263-B2 | Therapeutically active oxazoline derivatives | UCB BIOPHARMA SPRL (BE) | 2016-07-05 | — | — | US | disclosed |
| US-9227984-B2 | Therapeutically active fused pyrimidine derivatives | UCB PHARMA S.A. (BE) | 2016-01-05 | — | — | US | disclosed |
| US-20150274748-A1 | Therapeutically Active Oxazoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2015-10-01 | — | — | US | disclosed |
| EP-2903990-A1 | THERAPEUTICALLY ACTIVE OXAZOLINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2015-08-12 | — | — | EP | disclosed |
| US-20140309222-A1 | Therapeutically Active Fused Pyrimidine Derivatives | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2014-10-16 | — | — | US | disclosed |
| EP-2744812-A2 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-06-25 | — | — | EP | disclosed |
| WO-2014053581-A1 | THERAPEUTICALLY ACTIVE OXAZOLINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2014-04-10 | — | — | WO | disclosed |
| WO-2013024291-A2 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2013-02-21 | — | — | WO | disclosed |
| CN-101995770-A | Photoresist composition | SUMITOMO CHEMICAL CO | 2011-03-30 | — | — | CN | disclosed |
| US-20110033804-A1 | PHOTORESIST COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| US-7001706-B2 | Sulfonate and a resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20050014095-A1 | Sulfonate and a resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274748-A1 | Therapeutically Active Oxazoline Derivatives | ICOS, HAVCR2, CD74 | CES2 3523/4885CES1 2275/4885ALDH1A1 199/4885 |
| US-20140309222-A1 | Therapeutically Active Fused Pyrimidine Derivatives | HAVCR2, TPMT, PAICS | CES2 4370/4885CES1 2632/4885ALDH1A1 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.